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(EuroSCORE) and Society of Thoracic Surgeons (STS) score were
21.6  15.5 and 7.0  5.6, respectively. Rates of death at 30 days and
1 year were 3.4% and 10.6%, respectively. At 30 days, the incidence
of all stroke, major vascular complications, life-threatening
bleeding, and acute kidney injury (stage 2 or 3) were 3.0%, 5.2%, 7.6%
and 4.2%, respectively. Paravalvular regurgitation moderate or
greater occurred 9.5%. Device success rate and combined safety
endpoint at 30 days were 86.2% and 81.0%, respectively. In a multi-
variate model, female, chronic kidney disease, diabetes mellitus,
pulmonary disease, peripheral vascular disease, paravalvular regur-
gitation mild or greater, and STS score were signiﬁcantly associated
with reduced survival.
CONCLUSIONS This registry reﬂects the real-life experience of TAVR
in patients with increased risk in Asian Paciﬁc countries.
Clinical outcomes of TAVR in Asian Paciﬁc countriesOverall
(N [ 940)SAPIEN/XT
(N [ 615)CoreValve
(N[ 325) p valueMortality at 30
days3.4% 4.0% 2.5% 0.23Mortality at 1
year10.6% 7.6% 14.5% 0.02All stroke 3.0% 2.8% 3.4% 0.69Life-threatening
bleeding7.6% 8.1% 6.5% 0.36Acute kidney
injury stage 2-
34.3% 3.6% 5.5% 0.16Major vascular
complications5.2% 6.0% 3.7% 0.13Device success 86.2% 90.6% 78.1% < 0.001Safety endpoint 81.0% 80.3% 82.2% 0.51CATEGORIES STRUCTURAL: Valvular Disease: Aortic
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BACKGROUND High surgical risk and inoperable patients with severe
aortic stenosis (AS) undergoing TAVR often have reduced baseline
renal function. The impact of TAVR on improving this reduced base-
line renal function is unknown.
METHODS All patients undergoing TAVR from the PARTNER 1A (high
surgical risk), PARTNER 1B (inoperable), and both the randomized and
non-randomized continued access cohorts with glomerular ﬁltration
rate (GFR, utilizing the modiﬁcation of diet in renal disease formula) 
60 mL/min were analyzed. Patients were categorized as improved
GFR (30-day follow-up GFR 10% higher than baseline pre-TAVR
GFR), worsened GFR (30-day follow-up GFR 10% lower than baseline
pre-TAVR GFR), or no signiﬁcant change (not ﬁtting either previous
group). Baseline characteristics and 1-year all-cause mortality, as well
as repeat hospitalization rates, were compared between groups. Cox
regression models were used to determine multivariable predictors of
all-cause 1-year mortality.
RESULTS In total, 822 patients were analyzed, of which 345 (42%)
showed an improvement in GFR, 197 (24%) had worsening in GFR, and
280 (34%) had no signiﬁcant change in GFR. Comparing patients with
improved GFR with those with worsening GFR and those with no
signiﬁcant change in GFR, there was no difference in the mean age,
BMI, diabetes mellitus, COPD, CAD, PAD, pulmonary hypertension,
renal disease (Cr> 2 mg/dl), NYHA class III or IV symptoms, liver
disease, mean transaortic gradient, mean cardiac index, or mean
baseline EF. The improved GFR group had a greater percentage of
females (55.1% for improved GFR group vs. 40.1% for worsened GFR
group vs. 47.1% for no change group, p<0.01), lower median STS score
(10.9 vs. 11.0 vs. 10.6, p¼ 0.04), and had less smokers (39.4% vs. 54.6%
vs. 48.0%, p<0.01). Adjudicated 1-year all-cause mortality was lower
in the improved GFR group compared to the worsened and no sig-
niﬁcant change groups (15.4% vs. 25.8% vs. 19.1%, p<0.01), as well as
1-year repeat hospitalization (15.1% vs. 30.4 vs. 18.5% %, p<0.01). In a
multivariable analysis, after adjusting for age, gender, BMI, STS score,
diabetes mellitus, COPD, stroke or TIA, baseline ejection fraction,
prior CABG, and baseline GFR, improvement in GFR was associated
with reduced 1-year mortality (HR 0.51, 95% CI 0.34-0.76, p<0.01).
CONCLUSIONS Among those with reduced baseline GFR, TAVR re-
sults in an improvement in GFR in a substantial portion of patients.
Improvement in GFR following TAVR is independently associated
with a reduction in all-cause 1-year mortality in patients with severely
symptomatic AS who are at high surgical risk or are inoperable.
CATEGORIES STRUCTURAL: Valvular Disease: Aortic
KEYWORDS Renal function, Transcatheter aortic valve replacementTCT-94
Balloon Post-Dilation of the Self-Expanding CoreValve Transcatheter
Aortic Valve Bioprosthesis: Procedural Results and In Hospital Outcomes
from 3532 patients in the CoreValve US Pivotal and Continued Access Trials
J. Kevin Harrison,1 G.C. Hughes,2 Michael J. Reardon,3 Robert Stoler,4
Paul Grayburn,5 Robert F. Hebeler,4 Jeffrey Popma6
1Duke University Medical Center, Durham, NC; 2Duke University,
Durham, NC; 3Houston Methodist DeBakey Heart & Vascular Center,
Houston, TX; 4Baylor Heart and Vascular Hospital, Dallas, TX; 5Baylor
University Medical Center, Dallas, United States; 6Beth Israel
Deaconess Medical Center, Boston, MA
BACKGROUND The CoreValve self-expanding frame does not require
balloon expansion, but procedural post-dilation of the frame can be
performed in patients with suboptimal acute results. We sought to
deﬁne the incidence of balloon post-dilation (BPD) and the association
B44 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5of BPD with procedural and hospital outcomes in the CoreValve US
Pivotal and Continued Access Trials.
METHODS Patients in the CoreValve US Pivotal and Continued Access
trials were examined with respect to whether they underwent balloon
dilation of the CoreValve frame after valve implantation. Clinical,
anatomic, procedural and outcome data were analyzed. Best practice
guidelines in these trials recommended pre-dilation of the native
valve prior to CoreValve deployment, with BPD of the CoreValve
frame reserved for treatment of suboptimal intraprocedural stent
valve function.
RESULTS Procedural BPD was performed in 782 of 3532 patients (22%).
Male sex, larger aortic annular diameters, greater baseline aortic gra-
dients and aortic regurgitation (AR) were seen in the patients who
underwent balloon post-dilation (Table). The incidence of balloon pre-
dilation of the native valve and the CoreValve implant depth were
similar between those who did and did not undergo BPD. BPD was
performed less frequently with the 26 mm valve (17.9%) as compared to
the 31 mm valve (38.0%). The most common indication for BPD was 
moderate AR following CoreValve deployment which accounted for
58.1% of BPD patients. BPD was effective in acutely reducing AR in the
majority of these patients, with 78.0% with moderate AR having mild
or no AR after BPD. In-hospital major adverse cardiovascular and ce-
rebrovascular event rates were similar between no BPD (7.5%) and BPD
(9.3%) groups; p¼0.10. One case of valve migration and 3 cases of fatal
cardiac perforation occurred following BPD.
Table. Baseline CharacteristicsNo BPD
N [ 2750BPD
N [ 782 P ValueAge (years) 83.3  7.7 83.6  7.9 0.30
Female sex 49.3 % 37.5 % <0.0001Mean annular diameter
(mm)24.4  2.2 25.2  2.2 <0.0001Annular sizing ratio
<10%12.2% 24.0% <0.0001Mean aortic gradient
(mmHg)41.3  15.7 44.8  16.5 <0.0001Baseline AR 
moderate13.9% 21.5% <0.0001CONCLUSIONS Balloon post-dilation of the CoreValve bioprosthesis
was performed in 22% of patients in the CoreValve US Trials, most
commonly in patients with larger valve annulus measurements and
those with more severe baseline aortic valve dysfunction. The most
frequent indication for balloon post dilation was moderate or severe
aortic regurgitation. Balloon post-dilation was effective in acutely
improving valve performance and reducing aortic valve regurgitation
in the majority of these patients.
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BACKGROUND The long-term performance of SAPIEN transcatheter
aortic valve replacement (TAVR) is not known. Therefore, we exam-
ined the hemodynamic proﬁle of SAPIEN TAVR over 5 years of
follow-up and compared these results with surgical bioprosthetic
aortic valve replacement (SAVR).METHODS All patients receiving SAPIEN TAVR or SAVR with ﬁrst
post implant (FPI) and 5-year echoes were analyzed by an indepen-
dent echo core lab for: aortic valve (AV) peak velocity, AV mean
gradient, AV area (AVA), AVA indexed for body surface area, pre-stent
velocity in the left ventricular outﬂow tract (LVOT), in-stent (pre-
leaﬂet) velocity, time velocity integrals (TVI), Doppler velocity index
(DVI) and total, transvalvular and paravalvular aortic regurgitation
(AR). FPI and 5-year data were compared using paired t-test and
McNemar’s analyses.
RESULTS 91 SAPIEN TAVR and 48 SAVR patients had AV hemody-
namic assessments on FPI and 5 year echoes (Figure). AVA and AVA
index were unchanged 5 years after SAPIEN TAVR (p¼0.59 and
p¼0.72). AV mean gradient also did not change: 11.85.6 mmHg at
FPI to 10.96.1mmHg at 5 years, p¼0.21. In contrast, peak LVOT and
AV velocities decreased (both p¼0.02), as did in-stent velocity,
p¼0.01. Correspondingly, TAVR DVI using LVOT TVI or in-stent TVI
were unchanged, p¼0.16 and p¼0.09, respectively. There was no
signiﬁcant change in overall total AR (p¼0.32), paravalvular AR
(p¼0.11) or transvalvular AR (p¼0.71) over time among TAVR
patients. The results of longitudinal hemodynamic evaluation of
SAVR patients were similar to that seen in patients receiving
SAPIEN TAVR.
CONCLUSIONS Independent longitudinal assessment of the SAPIEN
TAVR shows that valve hemodynamics are stable 5 years after im-
plantation and similar to those for SAVR. These results indicate good
long term durability and support the use of TAVR in high-risk
patients.
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BACKGROUND Self-expanding transcatheter aortic valve replace-
ment (TAVR) is superior to medical therapy for pts with severe native
